Literature DB >> 2748489

Hematologic and bone marrow abnormalities in pediatric patients with human immunodeficiency virus (HIV) infection.

L M Sandhaus1, R Scudder.   

Abstract

This study presents the peripheral blood and bone marrow findings in eight children with perinatally acquired HIV infection, ranging in age from 5 months to 3 years. The indications for bone marrow examination were comparable to those for adults with HIV infection and included cytopenia(s), slenomegaly, failure to thrive, and suspected tuberculosis. Thrombocytopenia was the most common indication, and platelet-associated antibodies were elevated in all patients with thrombocytopenia. The peripheral blood morphology was remarkable for the presence of plasmacytosis and eosinophilia in those patients with lymphocytic interstitial pneumonia. Five patients had trephine biopsies, and marrow cellularity was normal with normal or increased megakaryocytes in all cases. Lymphoid aggregates, also described in adult patients with acquired immunodeficiency syndrome (AIDS), were present in three of five trephine biopsies. In contrast to the adult patients, myelodysplasia was not observed in the pediatric age group. None of the eight children had malignancies or opportunistic infections that were diagnosed by bone marrow examination.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748489     DOI: 10.3109/15513818909037732

Source DB:  PubMed          Journal:  Pediatr Pathol        ISSN: 0277-0938


  2 in total

1.  Erythropoiesis in HIV-infected and uninfected Malawian children with severe anemia.

Authors:  Job C J Calis; Kamija S Phiri; Raymond J W M Vet; Rob J de Haan; Francis Munthali; Robert J Kraaijenhagen; Paul J M Hulshof; Malcolm E Molyneux; Bernard J Brabin; Michaël Boele van Hensbroek; Imelda Bates
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 2.  An Approach to the Evaluation of Persistent Hypereosinophilia in Pediatric Patients.

Authors:  Justin T Schwartz; Patricia C Fulkerson
Journal:  Front Immunol       Date:  2018-09-03       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.